Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Syndax Pharma 730 Third Avenue 9th Floor New York NY 10017 USA

www.syndax.com Employees: 270 P: 781-419-1400 F: 781-419-1420

Sector:

Medical

Description:

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States.

Key Statistics

Overview:

Market Capitalization, $K 1,736,562
Enterprise Value, $K 1,926,172
Shares Outstanding, K 86,915
Annual Sales, $ 23,680 K
Annual Net Income, $ -318,760 K
Last Quarter Sales, $ 45,870 K
Last Quarter Net Income, $ -60,720 K
EBIT, $ -306,080 K
EBITDA, $ -319,510 K
60-Month Beta 0.47
% of Insider Shareholders 4.10%
Float, K 83,351
% Float 95.90%
Short Volume Ratio 0.53

Growth:

1-Year Return 25.58%
3-Year Return -18.18%
5-Year Return -20.87%
5-Year Revenue Growth 1,457.89%
5-Year Earnings Growth -102.17%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.70 on 11/03/25
Next Earnings Date 03/02/26
Earnings Per Share ttm -3.61
EPS Growth vs. Prev Qtr 15.66%
EPS Growth vs. Prev Year 28.57%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

SNDX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -160.60%
Return-on-Assets % -49.59%
Profit Margin % -1,346.11%
Debt/Equity 2.98
Price/Sales 74.58
Price/Cash Flow N/A
Price/Book 15.16
Book Value/Share 1.34
Interest Coverage -63.66
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar